Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Seaste Office of Public Records 232 Hart Building Washington, DC 20510

DECRETARY OF THE SENATE OD AUG -9 PM 5: 34

14.1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

Registant Name The Legislative Strategies Group				
2. Address	эп, D.C. 20004			
3. Principal Place of Business (if different from line 2)				
City: N.A. St	Be/Zip (or Country)			
4. Contact Name Felephone Katherine Merritt (202) 661-7960	E-mail (optional) 5. Senate 10 # 43651-			
7. Cliess Name	6. House ID # 34137			
8. TYPE OF REPORT Year 2000 Midyear (January 1-June 30) ☑ OR Year End (July 1-December 31) ☐ 9. Check if this filing amends a previously filed version of this report ☐ 10. Check if this is a Termination Report ☐ ➡ Termination Date				
INCOME OR EXPENSES - Complete Either Line 12 OR Line				
12. Lobbying Firms	13. Organizations			
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:			
Less than \$10,000 📑	Less than \$10,000 🗀			
\$10,000 or more 🗵 🗢 \$ 40,000 (name (rearest \$20,000)	\$10,000 or more			
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.			
	Method A. Reporting amounts using LDA definitions only			
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code			
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code			
Signature Jany & Smit				
Printed Name and Title Larry E. Smith, President	,AUG 1 0 2001			
From UD-2 (8587, 498)	Page 5 of 9			

Registrant Name The Legislative Strategie	s Group Client Name	Novartis Corporation	
	fient during the reporting	to reflect the general issue areas in which the regression. Using a separate page for each code,	
15. General issue area code MMM	(one per page)		
Specific lobbying issues Medical/Medicare device reimf Privacy of Health Information	pursement		
17. House(s) of Congress and Federal	agencies contacted	Check if None	
U.S. House of Representatives U.S. Senate	Health Care Financing Department of Health		
	•		
18. Name of each individual who acted	l as a lobbyist in this issu	de atea	
Name		Covered Official Position (if applicable)	New
		:	
Martin B. Gold	H 1-H-1:41-1:41-1:41-1:421-1 HXBXBX HXBXBX HI HI HZB HXB	: 	
Denise M. Henry	·///		-
Larry E. Smith	\$10		
Allison Giles			
Steven M. Hilton, Esq.		title = 12 14	0
G. David Mason			""
		The property of the property of the state of	۵
19. Interest of each foreign entity in th	e specific isspes listed o	n line 16 above 🖾 Check if None	r
Signature	T IPTIME ISSUES FILLER IN		
Printed Name and Title Larry E. S	rith Precident	August 9, 1999	
Tribles veeting and vitte	mar, (tobacit	<u> </u>	
			Page 2 of 5
From LD-2 (REV. 698)			1 mRc + ()()
From LDV2 (RDV2, 679) EDVE (RDV2 Profiles variety Lobbyting Reports Workship Section 5.406			

Filing #ec275ee8-7181-42bc-9c08-1026780646ac - Page 2 of 5

Novartis Corposation	
ry to reflect the general issue areas in which the reting period. Using a separate page for each code,	
☐ Check if None	
isue area	
Covered Official Position (if applicable)	New
	a
	0
	Ö
	Ü
on line 16 above 🖾 Check if None	
	cy to reflect the general issue areas in which the ring period. Using a separate page for each code, Check if None Covered Official Position (if applicable)

Registrant Name The Legislative Strategies Group Client Name	Nevartis Corporation	
LOBBYING ACTIVITY. Select as many codes as necessary engaged in lobbying on behalf of the client during the reportion information as requested. Attach additional page(s) as needed.		
15. General issue area code MED (one per page)		
16. Specific lobbying issues		
Clinical, laboratory and medical issues		
 House(s) of Congress and Federal agencies contacted U. S. House of Representatives United States Senate 	Check if None	
18. Name of each individual who acted as a lobbyist in this issu	រខ នុខន	
Name ·	Covered Official Position (if appticable)	New
Martin B. Gold		Q
Denise M. Henry	oorooooooooooooooooooooooooooooooooooo	
Larry E. Smith	MallMallMillatter	
Allison Giles		
Steven M. Hilton, Esq.		
G. David Mason	ANGASAH II HISH IMMAH PRIPATAN MANANAN PANAN PANAN PANAN MANAN MANAN MANAN MANAN MANAN MANAN MANAN MANAN MANAN	
19. Interest of each foreign entity in the specific issues listed o	n line 16 above 🗵 Check if None	
Signature		
Printed Name and Title <u>Larry E. Smith, President</u>		
		Page 4 of 5
CDL-2 (RREV. 498) CNWTSNT-Profiledvanial Lebbyrng Reportationaria Serám 5 dae		

Filing #ec275ee8-7181-42bc-9c08-1026780646ac - Page 4 of 5

Registrant Name The Legislative Strategies Group Client Name_	Novartis Corporation	
LOBBYING ACTIVITY. Select as many codes as necessary engaged in lobbying on behalf of the client during the reports information as requested. Attach additional page(s) as needed.	to reflect the general issue areas in which a ng period. Using a separate page for each co	he registrant ode, provide
15. General issue area code <u>PHA</u> (one per page)		
16. Specific lobbying issues		
Drug packaging, labeling and other pharmacy issues		
 House(s) of Congress and Federal agencies contacted U. S. House of Representatives United States Senate 	Check if None	
18. Name of each individual who acted as a lobbyist in this iss	ue area	
Name	Covered Official Position (if applicable)	New
Martin B. Gold		
, again and a state of the stat		Q
Denise M. Henry		- Ta
Larry E. Smith		
Allison Giles	,	
Steven M. Hilton, Esq.		-
G. David Mason		0
The state of the s	esti in ten nenen in siesti in sain in metalin in metalin iesti in et in metalisti in siesti in siesti in siesti	Q
19. Interest of each foreign entity in the specific issues listed of Signature	I line 16 above 🖾 Check if None	l
Printed Name and Title Larry E. Smith, President	August 9, 2000	

Page 5 of 5